Intelligence / Healthtech / New Clinical Trials / Trevi Therapeutics
Trevi Therapeutics
18 Nov 2026: Trial registered · A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 18 Nov 2026
- Title
- A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
- Conditions
- Healthy Participants
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- United States
- Country
- United States
- Reference
- NCT07946575
- Location
- United States
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Trevi Therapeutics
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.